替奈普酶治疗轻型致残性卒中的TEMPO-2二次分析
本文为TEMPO-2随机临床试验的二次分析,纳入886例轻型缺血性卒中(NIHSS 0-5)且证实颅内闭塞的患者,比较静脉替奈普酶(0.25 mg/kg)与非溶栓标准治疗。主要结局为90天恢复至基线mRS。结果显示,基于NIHSS的致残定义未改变替奈普酶的中性治疗效应。
要点
- 在致残组,替奈普酶组54.7% vs 标准治疗组68.1%达到主要结局(aRR 0.81,95%CI 0.60-1.10)。
- 基于NIHSS的致残定义未改变替奈普酶的中性治疗效应。
核心结论
- 在轻型卒中且颅内闭塞患者中,基于基线NIHSS的致残定义未改变静脉替奈普酶的中性治疗效应。
研究设计与样本
- TEMPO-2随机临床试验的二次分析,2015年4月27日至2024年1月19日于全球48个中心开展,随访90天。
- 纳入886例轻型缺血性卒中(NIHSS 0-5)且证实颅内闭塞、发病12小时内的患者,884例纳入二次分析。
- 干预为静脉替奈普酶(0.25 mg/kg)对比非溶栓标准治疗。
主要发现
- 884例患者中,100例(11.3%)为致残性缺陷,784例(88.7%)为非致残性缺陷。
- 致残组中,替奈普酶组29例(54.7%)vs 标准治疗组32例(68.1%)达到主要结局(aRR 0.81;95%CI 0.60-1.10)。
临床怎么用
- 对于轻型卒中且颅内闭塞患者,不应仅基于基线NIHSS定义的致残状态选择替奈普酶溶栓。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Outcomes following intravenous thrombolysis for minor ischemic stroke may vary based on the presence of disabling deficits. OBJECTIVE: To determine whether intravenous tenecteplase improves outcomes according to US National Institutes of Health Stroke Scale (NIHSS) score-based definitions of pretreatment disabling deficits. DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis of the TEMPO-2 (Tenecteplase vs Standard of Care for Minor Ischemic Stroke With Proven Occlusion) randomized clinical trial, conducted between April 27, 2015, and January 19, 2024. Patients were followed up for 90 days. The TEMPO-2 trial was conducted across 48 sites globally among patients with minor ischemic stroke (NIHSS 0-5) and proven intracranial occlusion within 12 hours of onset. Patients were divided into having nondisabling vs disabling syndromes at presentation as per the TREAT Task Force consensus. Other established definitions of disabling stroke from the ARAMIS trial and the National Institute of Neurological Disorders and Stroke trial were explored. Data analysis was completed from July 2024 to September 2024. INTERVENTIONS: Intravenous tenecteplase (0.25 mg/kg) vs nonthrombolytic standard of care. MAIN OUTCOMES AND MEASURES: The primary outcome was a return to baseline modified Rankin scale score at 90 days. RESULTS: Among 886 enrolled patients, 2 withdrew consent and 884 were included in the secondary analysis. Among 884 patients analyzed (369 women [41.7%]; median [IQR] age, 72 [61-80] years), 100 (11.3%) had disabling and 784 (88.7%) had nondisabling deficits. Patients with disabling deficits had higher median (IQR) baseline NIHSS scores (4 [3-5] vs 2 [1-3]), later presentations (onset to hospital arrival time: 288 [153-412] minutes vs 133 [70-310] minutes), and longer onset to treatment time (411 [307-560] minutes vs 278 [170-462] minutes) than those with nondisabling deficits. In the disabling group, the primary outcome following tenecteplase, compared with standard of care, occurred in 29 patients (54.7%) vs 32 patients (68.1%) (adjusted risk ratio [aRR], 0.81; 95% CI, 0.60-1.10). This neutral treatment effect was consistent in patients without disabling deficits (280 [73.9%] vs 306 [75.6%]; aRR, 0.98; 95% CI, 0.91-1.07; P for interaction = .32). CONCLUSIONS AND RELEVANCE: In this secondary analysis of the TEMPO-2 randomized clinical trial, current definitions of disabling symptoms based on NIHSS score at baseline did not modify the neutral treatment effect of intravenous tenecteplase in patients with minor stroke and intracranial occlusion. Together with converging evidence comparing intravenous thrombolysis to nonthrombolytic standard of care, this analysis suggests the need to reevaluate thrombolysis in minor disabling stroke. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02398656.
引用
- Zhang Y, Buck BH, Barber PA, et al. Thrombolysis With Tenecteplase for Minor Disabling Stroke: Secondary Analysis of the TEMPO-2 Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 41143808. doi:10.1001/jamaneurol.2025.4152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。